We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




10 Minute RT-PCR Point-of-Care System Detects Up To 32 Targets Per Sample

By LabMedica International staff writers
Posted on 21 Mar 2024

A 10-minute RT-PCR point-of-care (POC) system and respiratory panel are set to change the discussion on next-generation POC testing. More...

Autonomous Medical Devices Incorporated (AMDI, Santa Ana, CA, USA) is developing its Fast PCR System, a CLIA-waivable RT-PCR POC system that can detect up to 32 targets per sample in less than 10 minutes. The AMDI Fast PCR system is a compact, easy-to-use molecular point-of-care system that utilizes multiplexing capability specifically for CLIA-waived environments. It can run up to 32 targets at a time on a single sample in <10 minutes using a disposable disc without the need for a separate, offline sample preparation. At the core of the AMDI ultrafast system is the company’s Hyperbaric Heating (HBH) sample prep technology combined with its ultrafast PCR chemistry. The HBH technology eliminates the time constraints and costs associated with traditional sample preparation.

Combining HBH with AMDI’s ultrafast thermal cycling allows the test time to stay under 10 minutes regardless of the number of targets put on the test disc. The AMDI ultrafast system is designed to deliver highly sensitive, lab-quality results with the accessibility needed to address the testing needs of both the current and future pandemics. AMDI is also developing the first test panel for the Fast PCR system, targeting the detection of multiple respiratory viruses. The AMDI Respiratory Panel tests for the four most probable viruses that cause respiratory tract infections since the pandemic, including influenza A and B, respiratory syncytial virus, and SARS-CoV-2.

"Our market research indicates that our technology, when combined with cloud connectivity, can revolutionize patient care in the CLIA Waived setting," said David Okrongly, CEO of AMDI.

Related Links:
AMDI


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Gold Member
Latex Test
SLE-Latex Test
New
Clostridium Difficile Test
Immunocard Toxins A&B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The POC device rapidly predicts neonatal respiratory disease at birth in the NICU (Photo courtesy of SIME Diagnostics)

AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress

Each year, approximately 300,000 babies in the United States are born between 32 and 36 weeks' gestation, according to national health data. This group is at an elevated risk for respiratory distress,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: A biomarker discovery pipeline has shown promise as a noninvasive method of diagnosing CRC (Photo courtesy of NCI Center for Cancer Research)

Machine Learning Tool Enables Noninvasive Diagnosis and Monitoring of Colorectal Cancer

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States when considering both genders. Colonoscopy remains the gold standard for CRC diagnosis, but it is invasive,... Read more

Technology

view channel
Image: Scanning electron microscopy images showing 3D micro-printed Limacon-shaped whispering-gallery-mode microcavities with different amounts of deformation (Photo courtesy of A. Ping Zhang/PolyU)

Tiny Microlaser Sensors with Supercharged Biosensing Ability to Enable Early Disease Diagnosis

Optical whispering-gallery-mode microlaser sensors function by trapping light within tiny microcavities. When target molecules bind to the cavity, they induce subtle changes in the laser’s frequency, allowing... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.